Literature DB >> 11264188

Autoantibodies to alpha(IIb)beta(3) in patients with chronic immune thrombocytopenic purpura bind primarily to epitopes on alpha(IIb).

R McMillan1, J Lopez-Dee, J C Loftus.   

Abstract

Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disease caused by platelet destruction resulting from autoantibodies against platelet surface proteins, particularly platelet glycoprotein IIb/IIIa (alpha(IIb)beta(3)). To localize the auto-epitopes on platelet alpha(IIb)beta(3), the binding of autoantibodies to Chinese hamster ovary (CHO) cells expressing either alpha(IIb)beta(3) or alpha(v)beta(3) was studied. Thirteen of 14 ITP autoantibodies bound only to CHO cells expressing alpha(IIb)beta(3). Because these 2 integrins have the same beta chain (beta(3)), these results show that most epitopes in chronic ITP are dependent on the presence of glycoprotein alpha(IIb.) (Blood. 2001;97:2171-2172)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264188     DOI: 10.1182/blood.v97.7.2171

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Immunodiagnosis of platelet activation in immune thrombocytopenia through scFv antibodies cognate to activated IIb3 integrins.

Authors:  Preeti Bhoria; Neelam Varma; Pankaj Malhotra; Subhash Varma; Manni Luthra-Guptasarma
Journal:  MAbs       Date:  2015-08-24       Impact factor: 5.857

2.  Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia.

Authors:  D M Arnold; S Santoso; A Greinacher
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

3.  B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.

Authors:  Joseph M Tuscano; Jacob Sands
Journal:  Biologics       Date:  2009-07-13

Review 4.  Emerging Concepts in Immune Thrombocytopenia.

Authors:  Maurice Swinkels; Maaike Rijkers; Jan Voorberg; Gestur Vidarsson; Frank W G Leebeek; A J Gerard Jansen
Journal:  Front Immunol       Date:  2018-04-30       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.